SERVICE · TARGET DISCOVERY
PortraiTARGET
From tumor-selective ADCs to dual-targeting degraders — spatial transcriptomics + AI modeling + multi-dimensional validation reveal targets standard pipelines miss.
The sustainable engine for target discovery
A unified, AI-driven decision platform. We integrate one of the most comprehensive spatial transcriptomics datasets with in-silico prediction and rigorous validation to accelerate therapeutic development.
① DATA ENGINE
Anchored in human reality
Portrai has built one of the most comprehensive spatial transcriptomics databases available today — spanning over 2,000 patient samples and more than 50 million spatially resolved cells across key therapeutic areas. Fully integrated with clinical metadata to enable comparative analysis and benchmarking.
- 2,000+
- Patient samples
- 50M+
- Spatially resolved cells
- 7+
- Cancer types (NSCLC, SCLC, BRCA, COAD, PRAD, RCC, ESCA)
② PREDICTION ENGINE
Moving beyond human cognition
A specialized spatial biology engine that moves beyond bulk RNA-seq limitations. We decode the architecture of human tissue at single-cell resolution and turn it into target intelligence.
SERVICE · DRUG DISTRIBUTION
PortraiDRUG / PortraiMIX
Quantify drug distribution and mechanism-of-action in tissue via spatial transcriptomics. Applies to ADCs, mRNA, stem cell, and combination therapies.
AI MODEL · PATHOLOGY
PortraiTME™
Transforms H&E stained slides into pixel-level cell-type probability maps. NSCLC epithelial AUROC 0.96.
FOUNDATION MODEL
VGL — Vision·Gene·Language
A multimodal foundation model integrating images, genes, and language — for cancer cell classification and feature inference at scale.
③ VALIDATION ENGINE
From in-silico to physical assets
Predictions must be proven. Modality-aware validation translates AI-driven insights into physical assets — first computationally, then in tissue, then in vivo.
- 01 IN-SILICO
AI Prediction
Decode TME architecture, predict payload accumulation and off-target risks computationally.
- 02 WET-LAB
Parallel Validation
Validate ADCs & modality candidates in vitro. Spatial transcriptomics confirms co-localization.
- 03 IN-VIVO
Pre-clinical Imaging
POR006 and RPT assets advance to pre-clinical imaging and human imaging stages.
PRODUCT LINEUP
The Portrai product lineup
Service platform
PortraiTARGET
Therapeutic target discovery for ADCs, RPTs, bispecifics.
Service platform
PortraiDRUG / PortraiMIX
Drug distribution visualization and label-free spatial transcriptomics.
Service platform
PortraiMOA
Drug mechanism-of-action analysis.
AI model
PortraiTME™
H&E slide to spatial cell-type map (AI pathology).
Foundation model
V·G·L
VGL
Vision-Gene-Language multimodal model for cancer cell classification.
AI agent
PortrAIgent
Autonomous co-scientist for spatial transcriptomics analysis.
Software
Portrai Explorer
Spatial transcriptomics interactive visualization explorer.
Software (SaaS)
Portrai Insilicolab
Scientific project / data management platform for partners.
VALUE FOR PARTNERS
Accelerated by Portrai
Co-Discovery Partnerships
Collaborate with us to discover and validate novel targets using one of the largest spatial transcriptomics databases in oncology.
Asset Licensing
Access de-risked pre-clinical pipeline assets (POR-series) for rapid clinical advancement.
Infrastructure
Supported by global technology partners for secure, scalable spatial data computing.
READY TO ACCELERATE?
Ready to accelerate your pipeline?
See how Portrai's platform can de-risk drug discovery from spatial insights to life-changing therapies.